Shares of Array Biopharma Inc. (NASDAQ:ARRY) climbed 20.6 percent to $4.62 on Wednesday following news that its MEK inhibitor, binimetinib, improved progression-free survival (PFS) for patients with advanced NRAS-mutant melanoma compared to chemotherapy during the phase III Nemo study.
